ClinicalTrials.gg
RecruitingNCT06817564Updated Nov 13, 2026

AI-driven Personalized Exercise Feedback Program on Exercise Adherence in Traumatic Brain Injury

An interventional study of AI-PEF and Theory-based digital exercise in Traumatic Brain Injury, Exercise and AI (Artificial Intelligence), sponsored by National Defense Medical Center, Taiwan. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by National Defense Medical Center, Taiwan · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 13, 2026Now RecruitingFirst site in Taiwan+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Brain Injuries, Traumatic with a site in Taiwan — 4 open to participants now, 4 under way, none of them phase 3. Brain Injuries, Traumatic · Taiwan.

Planned enrollment
Largest of 16
125 · median 71
Started
2026
the only one that year
No phase
15 of 19
4 open now
Registered
18th of 19
by date
Lead sponsor
1 of 19
National Defense Medical Center, Taiwan

Among the 19 studies in Brain Injuries, Traumatic with a site in Taiwan, this one has the largest planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is one of 15 with no phase, and was the 18th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

4 of the 19 studies in Brain Injuries, Traumatic with a site in Taiwan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Brain Injuries, Traumatic with a site in Taiwan, or all of them as a file.
02

Study summary

This study aims to develop and evaluate an AI-driven Personalized Exercise Feedback Program (AI-PEF) to enhance exercise adherence and health outcomes in mTBI patients.

Methods: AI-PEF integrates the transtheoretical model and self-determination theory with machine learning algorithms to provide real-time, personalized feedback. A phased randomized controlled trial will be conducted: Phase I evaluates feasibility and acceptability through Delphi methods with expert consensus and patient feedback; Phase II validates preliminary outcomes with 30 participants in a 2-arm randomized trial; and Phase III assesses the program's impact on exercise motivation, exercise adherence, functional exercise capacity, post-concussion symptoms, depressive symptoms, sleep quality, physical activity, quality of life, cognitive function, prefrontal cerebral blood flow, cardiac metabolic performance, physiological monitoring, and mHealth app usability with 90 participants in a 3-arm randomized trial. In Phase III, quantitative and qualitative data will be collected in parallel, with qualitative data collected through semi-structured interviews to explore participants' experiences and perceptions of the intervention.

Read the detailed description

The study will employ a stepwise, multi-phase design, combining a two- parallel-group pilot study and a three-arm randomized controlled trial (RCT) to evaluate the appropriateness, feasibility, acceptability, and effectiveness of the AI-PEF (Figure 5). Participants will be recruited from the neurosurgery clinics at Tri-Service General Hospital, Taipei. Recruitment will be facilitated through referrals by attending physicians and registered nurses, who will be briefed on the study protocol.

Study procedures

  1. Phase I (Year 1): Development and Pilot Testing (Aim 1) Phase I will focus on developing and refining the AI-PEF through expert validation and pilot testing. This phase will use a sequential-parallel hybrid design to develop and evaluate the appropriateness of the AI-PEF to deliver personalized exercise empowerment. Stage 1, Delphi Process for AI-PEF Development: Ten experts from diverse fields will participate in two Delphi rounds to finalize the AI-PEF framework. This includes refining algorithms, educational materials, and preliminary validation of key components, such as personalization algorithms and behavior-change strategies. Stage 2, Small-Scale Pilot Study (Early Feedback): A single-arm pilot study with 5 patients will be conducted over four weeks to gather feedback on usability, engagement, and content clarity.
  2. Phase II : Larger Pilot Study (Aim 2) Phase II will focus on evaluating the feasibility, acceptability, and preliminary effectiveness of the refined AI-PEF intervention. A two-parallel-group design will be employed, with 30 participants, 15 participants per group, randomly assigned in a 1:1 ratio to the AI-PEF group and Active control group. Over three months, AI-PEF participants will engage in personalized exercise guided by AI, while active control participants will follow standard exercise recommendations. Both qualitative and quantitative data will be collected. Assessments will occur at baseline (T0) and 3 months (T1), including fitness tracker data, questionnaires (motivation, sleep, symptoms), and semi-structured interviews. The primary outcome of interest will be adherence rates, while secondary outcomes will focus on motivation and various health metrics.
  3. Phase III : Full- scale three-arm RCT (Aim 3) Phase III will assess the long-term impact of the AI-PEF on exercise motivation, adherence, and health outcomes through a 3-arm RCT, in which participants will be randomly assigned in a 1:1:1 ratio to one of three groups: (1) the AI-PEF group, receiving a machine learning-powered personalized exercise program; (2) the Theory-based digital exercise group, engaging in structured digital exercise without machine learning-powered feedback; or (3) the Active control group, receiving general exercise recommendations as part of standard care. Participants in the AI-PEF and theory-based digital exercise groups will follow a 24-week walking program. All three groups will receive five LINE messages per week during the initial 12 weeks, while the AI-PEF group will continue receiving these messages through week 24. Participants will be followed for six months, with assessments conducted at baseline (T0), 1 month (T1), 2 months (T2), 3 months (T3), and the 6-month follow-up (T4).

Primary outcomes will include exercise motivation, exercise adherence, and functional exercise capacity. Exercise motivation will be assessed through standardized questionnaires; exercise adherence will be objectively measured via Garmin fitness trackers; and functional capacity will be evaluated using the 6-Minute Walk Test. Secondary outcomes, including post-concussion symptoms, depressive symptoms, sleep quality, physical activity, quality of life, cognitive function, prefrontal cerebral blood flow, cardiac metabolic performance, physiological monitoring, and mHealth app usability, will be assessed using questionnaires, cognitive and physiological assessments, and wearable device data, as appropriate. These standardized questionnaires are being used in our current digital remote exercise trial in patients with mild TBI (NSTC 112-2314-B-016-007-MY2) and have demonstrated good psychometric performance.

Quantitative and qualitative data will be collected and analyzed in parallel. Quantitative data will be used to compare exercise motivation, exercise adherence, functional exercise capacity, and secondary outcomes across the three groups and to evaluate the efficacy of AI-PEF relative to standard interventions. Qualitative interviews will explore participants' experiences and perceptions of the intervention. Procedures will adhere to the blinding and randomization protocols described in Intervention Fidelity, ensuring unbiased assignment and data collection processes. This proposed study protocol is closely aligned with those that have been successfully implemented in our previous digital exercise trial.

03

Conditions studied

  • Traumatic Brain Injury
  • Exercise
  • AI (Artificial Intelligence)
  • Digital Health

Keywords

  • AI-Driven Personalized Exercise Program
04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible participants are patients aged 18 years or older with mild TBI (GCS 13-15) diagnosed within the previous 6 months.
  • who can walk independently and have been cleared by the attending physician to participate in exercise.
  • have access to a smartphone and can use mobile messaging and wearable device applications.
  • and possess sufficient Chinese or Taiwanese language proficiency to understand the trial .
  • complete self-administered questionnaires.

Exclusion criteria

Exclusion Criteria:

  • include individuals with severe medical conditions (e.g., respiratory failure, epilepsy, psychiatric disorders), musculoskeletal or neurological impairments.
  • hindering physical activity in the 6-minute walk test.
  • cognitive impairments ( \< 24).
  • frontal lobe injuries or penetrating injury causing significant psychological dysfunction.
  • Patients concurrently participating in other clinical trials or structured exercise programs will also be excluded to avoid bias.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
125 participants (estimated)

Study arms

  • Experimental
    AI-PEF

    the AI-PEF group, receiving a machine learning-powered personalized exercise program.

    Behavioral: AI-PEF

  • Experimental
    Theory-based digital exercise

    Theory-based digital exercise group, engaging in structured digital exercise without machine learning- powered feedback.

    Behavioral: Theory-based digital exercise

  • Active comparator
    Active control group

    the Active control group, receiving general exercise recommendations as part of standard care in a 1:1:1 ratio.

    Behavioral: Active Control

Interventions

  • BehavioralAI-PEF

    Participants will follow a 24-week walking program with at least three 30-minute sessions per week, with exercise intensity progressively adjusted based on heart rate and effort indices. Garmin fitness trackers will monitor exercise adherence and intensity. Remote guidance will be provided through five AI-generated digital health messages per week via LINE, delivered on Monday, Tuesday, Thursday, Friday, and Saturday, and tailored to participants' exercise performance and individualized goals established during the remote exercise intervention and consultation. The messages will include exercise performance feedback, goal setting and reinforcement, exercise and device-use reminders, health education, and encouragement and support. The digital component will allow participants to share their progress and seek guidance during scheduled in-person consultations. AI-driven digital feedback provides a convenient and accessible approach to supporting participants in engaging in exercise.

  • BehavioralTheory-based digital exercise

    The theory-based digital exercise group will follow the same in-person clinic visits, assessment schedule, and 24-week walking program as the AI-PEF group. Garmin fitness trackers will be used to monitor exercise adherence and intensity. The research team will deliver five standardized digital health messages per week during the initial 12 weeks through the LINE app using message templates developed in advance. The messages will include exercise guidance, goal setting and reinforcement, exercise and device-use reminders, health education and lifestyle recommendations, and encouragement and support. The messages will not be generated or tailored by AI, and participants will not receive AI-driven personalized feedback.

  • BehavioralActive Control

    Participants in the active control group will receive standard TBI care, including routine clinic visits. In addition, Garmin fitness trackers will be provided for self-monitoring during the study. The research team will deliver five standardized general health messages per week during the initial 12 weeks through the LINE app. The messages will include TBI-related health education, general health and lifestyle information, general recommendations for daily physical activity, general check-in messages, and technical reminders for Garmin use. The messages will not include structured exercise guidance, individualized goal setting or reinforcement, performance-based feedback, or AI-generated personalized feedback. Participants completing the 6-month protocol will have the option to access the AI-PEF program after the study.

06

What researchers measure

Primary outcomes

  1. The Chinese Version of the Sport Motivation Scale-II

    The Chinese version of the Sport Motivation Scale-II (CSMS-II) will be used to assess six types of motivation: intrinsic motivation, integrated regulation, identified regulation, introjected regulation, external regulation, and amotivation. The scale consists of 18 items rated on a 7-point Likert scale from 1 to 7. The subscales include intrinsic motivation (items 3, 9, and 17), integrated regulation (items 4, 11, and 14), identified regulation (items 6, 12, and 18), introjected regulation (items 1, 7, and 16), external regulation (items 5, 8, and 15), and amotivation (items 2, 10, and 13). Each subscale is scored separately by calculating the mean of its three items. Each subscale score ranges from 1 to 7, with higher scores indicating a stronger level of the corresponding motivational regulation.

    Time frame: T0- baseline

  2. The Chinese Version of the Sport Motivation Scale-II

    The Chinese version of the Sport Motivation Scale-II (CSMS-II) will be used to assess six types of motivation: intrinsic motivation, integrated regulation, identified regulation, introjected regulation, external regulation, and amotivation. The scale consists of 18 items rated on a 7-point Likert scale from 1 to 7. The subscales include intrinsic motivation (items 3, 9, and 17), integrated regulation (items 4, 11, and 14), identified regulation (items 6, 12, and 18), introjected regulation (items 1, 7, and 16), external regulation (items 5, 8, and 15), and amotivation (items 2, 10, and 13). Each subscale is scored separately by calculating the mean of its three items. Each subscale score ranges from 1 to 7, with higher scores indicating a stronger level of the corresponding motivational regulation.

    Time frame: T1- 1 month later

  3. The Chinese Version of the Sport Motivation Scale-II

    The Chinese version of the Sport Motivation Scale-II (CSMS-II) will be used to assess six types of motivation: intrinsic motivation, integrated regulation, identified regulation, introjected regulation, external regulation, and amotivation. The scale consists of 18 items rated on a 7-point Likert scale from 1 to 7. The subscales include intrinsic motivation (items 3, 9, and 17), integrated regulation (items 4, 11, and 14), identified regulation (items 6, 12, and 18), introjected regulation (items 1, 7, and 16), external regulation (items 5, 8, and 15), and amotivation (items 2, 10, and 13). Each subscale is scored separately by calculating the mean of its three items. Each subscale score ranges from 1 to 7, with higher scores indicating a stronger level of the corresponding motivational regulation.

    Time frame: T2- 2 month later

  4. The Chinese Version of the Sport Motivation Scale-II

    The Chinese version of the Sport Motivation Scale-II (CSMS-II) will be used to assess six types of motivation: intrinsic motivation, integrated regulation, identified regulation, introjected regulation, external regulation, and amotivation. The scale consists of 18 items rated on a 7-point Likert scale from 1 to 7. The subscales include intrinsic motivation (items 3, 9, and 17), integrated regulation (items 4, 11, and 14), identified regulation (items 6, 12, and 18), introjected regulation (items 1, 7, and 16), external regulation (items 5, 8, and 15), and amotivation (items 2, 10, and 13). Each subscale is scored separately by calculating the mean of its three items. Each subscale score ranges from 1 to 7, with higher scores indicating a stronger level of the corresponding motivational regulation.

    Time frame: T3- 3 month later

  5. The Chinese Version of the Sport Motivation Scale-II

    The Chinese version of the Sport Motivation Scale-II (CSMS-II) will be used to assess six types of motivation: intrinsic motivation, integrated regulation, identified regulation, introjected regulation, external regulation, and amotivation. The scale consists of 18 items rated on a 7-point Likert scale from 1 to 7. The subscales include intrinsic motivation (items 3, 9, and 17), integrated regulation (items 4, 11, and 14), identified regulation (items 6, 12, and 18), introjected regulation (items 1, 7, and 16), external regulation (items 5, 8, and 15), and amotivation (items 2, 10, and 13). Each subscale is scored separately by calculating the mean of its three items. Each subscale score ranges from 1 to 7, with higher scores indicating a stronger level of the corresponding motivational regulation.

    Time frame: T4- 6 month later

  6. Adherence

    Exercise adherence will be objectively assessed using Garmin vivosmart 5 wearable device data. A recorded exercise session lasting at least 30 minutes will be counted as completed, with a maximum of three sessions counted per week. Adherence will be calculated as the number of completed sessions during the specified assessment interval divided by three times the number of weeks in that interval, multiplied by 100. Scores range from 0% to 100%, with higher percentages indicating greater adherence. The total target over 24 weeks is 72 sessions. Days without wearable device data will not count as completed sessions, and the denominator will remain unchanged.

    Time frame: T1- 1 month later

  7. Adherence

    Exercise adherence will be objectively assessed using Garmin vivosmart 5 wearable device data. A recorded exercise session lasting at least 30 minutes will be counted as completed, with a maximum of three sessions counted per week. Adherence will be calculated as the number of completed sessions during the specified assessment interval divided by three times the number of weeks in that interval, multiplied by 100. Scores range from 0% to 100%, with higher percentages indicating greater adherence. The total target over 24 weeks is 72 sessions. Days without wearable device data will not count as completed sessions, and the denominator will remain unchanged.

    Time frame: T2- 2 month later

  8. Adherence

    Exercise adherence will be objectively assessed using Garmin vivosmart 5 wearable device data. A recorded exercise session lasting at least 30 minutes will be counted as completed, with a maximum of three sessions counted per week. Adherence will be calculated as the number of completed sessions during the specified assessment interval divided by three times the number of weeks in that interval, multiplied by 100. Scores range from 0% to 100%, with higher percentages indicating greater adherence. The total target over 24 weeks is 72 sessions. Days without wearable device data will not count as completed sessions, and the denominator will remain unchanged.

    Time frame: T3- 3 month later

  9. Adherence

    Exercise adherence will be objectively assessed using Garmin vivosmart 5 wearable device data. A recorded exercise session lasting at least 30 minutes will be counted as completed, with a maximum of three sessions counted per week. Adherence will be calculated as the number of completed sessions during the specified assessment interval divided by three times the number of weeks in that interval, multiplied by 100. Scores range from 0% to 100%, with higher percentages indicating greater adherence. The total target over 24 weeks is 72 sessions. Days without wearable device data will not count as completed sessions, and the denominator will remain unchanged.

    Time frame: T4- 6 month later

  10. 6-Minute Walk Test

    Functional capacity will be evaluated using the 6-Minute Walk Test (6MWT), which measures the distance walked in six minutes as an indicator of functional exercise capacity. A longer walking distance indicates better functional capacity.

    Time frame: T0- baseline

  11. 6-Minute Walk Test

    Functional capacity will be evaluated using the 6-Minute Walk Test (6MWT), which measures the distance walked in six minutes as an indicator of functional exercise capacity. A longer walking distance indicates better functional capacity.

    Time frame: T1- 1 month later

  12. 6-Minute Walk Test

    Functional capacity will be evaluated using the 6-Minute Walk Test (6MWT), which measures the distance walked in six minutes as an indicator of functional exercise capacity. A longer walking distance indicates better functional capacity.

    Time frame: T2- 2 month later

  13. 6-Minute Walk Test

    Functional capacity will be evaluated using the 6-Minute Walk Test (6MWT), which measures the distance walked in six minutes as an indicator of functional exercise capacity. A longer walking distance indicates better functional capacity.

    Time frame: T3- 3 month later

  14. 6-Minute Walk Test

    Functional capacity will be evaluated using the 6-Minute Walk Test (6MWT), which measures the distance walked in six minutes as an indicator of functional exercise capacity. A longer walking distance indicates better functional capacity.

    Time frame: T4- 6 month later

Secondary outcomes

  1. The Rivermead Post-Concussion Symptoms Questionnaire

    The Rivermead Post-Concussion Symptoms Questionnaire (RPQ) will assess physical, cognitive, and behavioral symptoms associated with TBI, validated for mild to moderate TBI cases. A total of 16 items, scored 0-4, ranged 0- 64, the higher scores mean the severity of the concussion symptoms.

    Time frame: T0- baseline

  2. The Rivermead Post-Concussion Symptoms Questionnaire

    The Rivermead Post-Concussion Symptoms Questionnaire (RPQ) will assess physical, cognitive, and behavioral symptoms associated with TBI, validated for mild to moderate TBI cases. A total of 16 items, scored 0-4, ranged 0- 64, the higher scores mean the severity of the concussion symptoms.

    Time frame: T1- 1 month later

  3. The Rivermead Post-Concussion Symptoms Questionnaire

    The Rivermead Post-Concussion Symptoms Questionnaire (RPQ) will assess physical, cognitive, and behavioral symptoms associated with TBI, validated for mild to moderate TBI cases. A total of 16 items, scored 0-4, ranged 0- 64, the higher scores mean the severity of the concussion symptoms.

    Time frame: T2- 2 month later

  4. The Rivermead Post-Concussion Symptoms Questionnaire

    The Rivermead Post-Concussion Symptoms Questionnaire (RPQ) will assess physical, cognitive, and behavioral symptoms associated with TBI, validated for mild to moderate TBI cases. A total of 16 items, scored 0-4, ranged 0- 64, the higher scores mean the severity of the concussion symptoms.

    Time frame: T3- 3 month later

  5. The Rivermead Post-Concussion Symptoms Questionnaire

    The Rivermead Post-Concussion Symptoms Questionnaire (RPQ) will assess physical, cognitive, and behavioral symptoms associated with TBI, validated for mild to moderate TBI cases. A total of 16 items, scored 0-4, ranged 0- 64, the higher scores mean the severity of the concussion symptoms.

    Time frame: T4- 6 month

  6. The Beck Depression Inventory-II

    The Beck Depression Inventory-II (BDI-II), with total scores categorized as follows: 0-13 (normal), 14-19 (mild depression), 20-28 (moderate depression), and 29-63 (severe depression), will evaluate depressive symptoms with established reliability (α = 0.94) and validity.

    Time frame: T0- baseline

  7. The Beck Depression Inventory-II

    The Beck Depression Inventory-II (BDI-II), with total scores categorized as follows: 0-13 (normal), 14-19 (mild depression), 20-28 (moderate depression), and 29-63 (severe depression), will evaluate depressive symptoms with established reliability (α = 0.94) and validity.

    Time frame: T1-1 month later

  8. The Beck Depression Inventory-II

    The Beck Depression Inventory-II (BDI-II), with total scores categorized as follows: 0-13 (normal), 14-19 (mild depression), 20-28 (moderate depression), and 29-63 (severe depression), will evaluate depressive symptoms with established reliability (α = 0.94) and validity.

    Time frame: T2- 2 month later

  9. The Beck Depression Inventory-II

    The Beck Depression Inventory-II (BDI-II), with total scores categorized as follows: 0-13 (normal), 14-19 (mild depression), 20-28 (moderate depression), and 29-63 (severe depression), will evaluate depressive symptoms with established reliability (α = 0.94) and validity.

    Time frame: T3-3 month later

  10. The Beck Depression Inventory-II

    The Beck Depression Inventory-II (BDI-II), with total scores categorized as follows: 0-13 (normal), 14-19 (mild depression), 20-28 (moderate depression), and 29-63 (severe depression), will evaluate depressive symptoms with established reliability (α = 0.94) and validity.

    Time frame: T4- 6 month later

  11. The Pittsburgh Sleep Quality Index

    The Pittsburgh Sleep Quality Index (PSQI) will assess subjective sleep quality, using a validated Chinese version. Previous research has demonstrated good internal consistency reliability (0.82) and 14- to 21-day test-retest reliability (0.85) of the PSQI Chinese version in Taiwan's populations. Each component score of the PSQI ranges from 0 to 3, with 3 indicating the greatest dysfunction or disturbance. The seven component scores are then summed to obtain a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties.

    Time frame: T0-baseline

  12. The Pittsburgh Sleep Quality Index

    The Pittsburgh Sleep Quality Index (PSQI) will assess subjective sleep quality, using a validated Chinese version \[68\]. Previous research has demonstrated good internal consistency reliability (0.82) and 14- to 21-day test-retest reliability (0.85) of the PSQI Chinese version in Taiwan's populations. Each component score of the PSQI ranges from 0 to 3, with 3 indicating the greatest dysfunction or disturbance. The seven component scores are then summed to obtain a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties

    Time frame: T1- 1 month later

  13. The Pittsburgh Sleep Quality Index

    The Pittsburgh Sleep Quality Index (PSQI) will assess subjective sleep quality, using a validated Chinese version \[68\]. Previous research has demonstrated good internal consistency reliability (0.82) and 14- to 21-day test-retest reliability (0.85) of the PSQI Chinese version in Taiwan's populations. Each component score of the PSQI ranges from 0 to 3, with 3 indicating the greatest dysfunction or disturbance. The seven component scores are then summed to obtain a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties

    Time frame: T2-2 month later

  14. The Pittsburgh Sleep Quality Index

    The Pittsburgh Sleep Quality Index (PSQI) will assess subjective sleep quality, using a validated Chinese version \[68\]. Previous research has demonstrated good internal consistency reliability (0.82) and 14- to 21-day test-retest reliability (0.85) of the PSQI Chinese version in Taiwan's populations. Each component score of the PSQI ranges from 0 to 3, with 3 indicating the greatest dysfunction or disturbance. The seven component scores are then summed to obtain a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties

    Time frame: T3-3 month later

  15. The Pittsburgh Sleep Quality Index

    The Pittsburgh Sleep Quality Index (PSQI) will assess subjective sleep quality, using a validated Chinese version \[68\]. Previous research has demonstrated good internal consistency reliability (0.82) and 14- to 21-day test-retest reliability (0.85) of the PSQI Chinese version in Taiwan's populations. Each component score of the PSQI ranges from 0 to 3, with 3 indicating the greatest dysfunction or disturbance. The seven component scores are then summed to obtain a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties

    Time frame: T4-6 month later

  16. The Godin-Shephard Leisure Time Physical Activity Questionnaire

    The Godin-Shephard Leisure Time Physical Activity Questionnaire (GLTPA) will measure weekly physical activity intensity, classified into light, moderate, and vigorous levels. The Chinese version of the GLTPA has shown good validity and is significantly correlated with mental health outcomes. By classifying physical activity intensity lasting for more than 15 minutes in the past week into strenuous activities, moderate strenuous activities, and light activities, and then multiplying by corresponding coefficients 9, 5, and 3 respectively for quantification, the sum of these scores is Godin's leisure time physical Total activity score, with higher scores indicating greater physical activity. The level of physical activity can be divided into three levels according to the total Godin leisure time physical activity score. A total score of 24 or above is considered active, a score between 14 and 23 is moderately active, and a score below 14 is consider Insufficiently active.

    Time frame: T0 -baseline

  17. The Godin-Shephard Leisure Time Physical Activity Questionnaire

    The Godin-Shephard Leisure Time Physical Activity Questionnaire (GLTPA) will measure weekly physical activity intensity, classified into light, moderate, and vigorous levels. The Chinese version of the GLTPA has shown good validity and is significantly correlated with mental health outcomes. By classifying physical activity intensity lasting for more than 15 minutes in the past week into strenuous activities, moderate strenuous activities, and light activities, and then multiplying by corresponding coefficients 9, 5, and 3 respectively for quantification, the sum of these scores is Godin's leisure time physical Total activity score, with higher scores indicating greater physical activity. The level of physical activity can be divided into three levels according to the total Godin leisure time physical activity score. A total score of 24 or above is considered active, a score between 14 and 23 is moderately active, and a score below 14 is consider Insufficiently active .

    Time frame: T1 -1 month later

  18. The Godin-Shephard Leisure Time Physical Activity Questionnaire

    The Godin-Shephard Leisure Time Physical Activity Questionnaire (GLTPA) will measure weekly physical activity intensity, classified into light, moderate, and vigorous levels. The Chinese version of the GLTPA has shown good validity and is significantly correlated with mental health outcomes. By classifying physical activity intensity lasting for more than 15 minutes in the past week into strenuous activities, moderate strenuous activities, and light activities, and then multiplying by corresponding coefficients 9, 5, and 3 respectively for quantification, the sum of these scores is Godin's leisure time physical Total activity score, with higher scores indicating greater physical activity. The level of physical activity can be divided into three levels according to the total Godin leisure time physical activity score. A total score of 24 or above is considered active, a score between 14 and 23 is moderately active, and a score below 14 is consider Insufficiently active.

    Time frame: T2 -2 month later

  19. The Godin-Shephard Leisure Time Physical Activity Questionnaire

    The Godin-Shephard Leisure Time Physical Activity Questionnaire (GLTPA) will measure weekly physical activity intensity, classified into light, moderate, and vigorous levels. The Chinese version of the GLTPA has shown good validity and is significantly correlated with mental health outcomes. By classifying physical activity intensity lasting for more than 15 minutes in the past week into strenuous activities, moderate strenuous activities, and light activities, and then multiplying by corresponding coefficients 9, 5, and 3 respectively for quantification, the sum of these scores is Godin's leisure time physical Total activity score, with higher scores indicating greater physical activity. The level of physical activity can be divided into three levels according to the total Godin leisure time physical activity score. A total score of 24 or above is considered active, a score between 14 and 23 is moderately active, and a score below 14 is consider Insufficiently active.

    Time frame: T3-3 month later

  20. The Godin-Shephard Leisure Time Physical Activity Questionnaire

    The Godin-Shephard Leisure Time Physical Activity Questionnaire (GLTPA) will measure weekly physical activity intensity, classified into light, moderate, and vigorous levels. The Chinese version of the GLTPA has shown good validity and is significantly correlated with mental health outcomes. By classifying physical activity intensity lasting for more than 15 minutes in the past week into strenuous activities, moderate strenuous activities, and light activities, and then multiplying by corresponding coefficients 9, 5, and 3 respectively for quantification, the sum of these scores is Godin's leisure time physical Total activity score, with higher scores indicating greater physical activity. The level of physical activity can be divided into three levels according to the total Godin leisure time physical activity score. A total score of 24 or above is considered active, a score between 14 and 23 is moderately active, and a score below 14 is consider Insufficiently active.

    Time frame: T4-6 month later

  21. The World Health Organization Quality of Life Scale-brief

    The World Health Organization Quality of Life Scale-brief (WHOQOL-BREF), validated in Chinese, with good internal consistency (α = 0.70-0.77), overall reliability (α = 0.91), and test-retest reliability (0.76-0.80), will assess the quality of life across four domains: physical, psychological, social, and environmental well-being. This scale covers subjective life feelings in four major categories: physical health, psychological, social relations, and environment. It has 24 questions in total. There are also 2 questions measuring the overall quality of life and general health at the general level. (general health), in addition, the Taiwan version adds 2 local questions, namely diet (whether you can eat the food you want) and face issues (whether you are respected), a total of 28 questions, and the scores for each category are introduced. Between 4 and 20, the higher the score, the better the quality of life.

    Time frame: T0 - baseline

  22. The World Health Organization Quality of Life Scale-brief

    The World Health Organization Quality of Life Scale-brief (WHOQOL-BREF), validated in Chinese, with good internal consistency (α = 0.70-0.77), overall reliability (α = 0.91), and test-retest reliability (0.76-0.80), will assess the quality of life across four domains: physical, psychological, social, and environmental well-being. This scale covers subjective life feelings in four major categories: physical health, psychological, social relations, and environment. It has 24 questions in total. There are also 2 questions measuring the overall quality of life and general health at the general level. (general health), in addition, the Taiwan version adds 2 local questions, namely diet (whether you can eat the food you want) and face issues (whether you are respected), a total of 28 questions, and the scores for each category are introduced. Between 4 and 20, the higher the score, the better the quality of life.

    Time frame: T1 - 1 month later

  23. The World Health Organization Quality of Life Scale-brief

    The World Health Organization Quality of Life Scale-brief (WHOQOL-BREF), validated in Chinese, with good internal consistency (α = 0.70-0.77), overall reliability (α = 0.91), and test-retest reliability (0.76-0.80), will assess the quality of life across four domains: physical, psychological, social, and environmental well-being. This scale covers subjective life feelings in four major categories: physical health, psychological, social relations, and environment. It has 24 questions in total. There are also 2 questions measuring the overall quality of life and general health at the general level. (general health), in addition, the Taiwan version adds 2 local questions, namely diet (whether you can eat the food you want) and face issues (whether you are respected), a total of 28 questions, and the scores for each category are introduced. Between 4 and 20, the higher the score, the better the quality of life.

    Time frame: T2 - 2 month later

  24. The World Health Organization Quality of Life Scale-brief

    The World Health Organization Quality of Life Scale-brief (WHOQOL-BREF), validated in Chinese, with good internal consistency (α = 0.70-0.77), overall reliability (α = 0.91), and test-retest reliability (0.76-0.80), will assess the quality of life across four domains: physical, psychological, social, and environmental well-being. This scale covers subjective life feelings in four major categories: physical health, psychological, social relations, and environment. It has 24 questions in total. There are also 2 questions measuring the overall quality of life and general health at the general level. (general health), in addition, the Taiwan version adds 2 local questions, namely diet (whether you can eat the food you want) and face issues (whether you are respected), a total of 28 questions, and the scores for each category are introduced. Between 4 and 20, the higher the score, the better the quality of life.

    Time frame: T3- 3 month later

  25. The World Health Organization Quality of Life Scale-brief

    The World Health Organization Quality of Life Scale-brief (WHOQOL-BREF), validated in Chinese, with good internal consistency (α = 0.70-0.77), overall reliability (α = 0.91), and test-retest reliability (0.76-0.80), will assess the quality of life across four domains: physical, psychological, social, and environmental well-being. This scale covers subjective life feelings in four major categories: physical health, psychological, social relations, and environment. It has 24 questions in total. There are also 2 questions measuring the overall quality of life and general health at the general level. (general health), in addition, the Taiwan version adds 2 local questions, namely diet (whether you can eat the food you want) and face issues (whether you are respected), a total of 28 questions, and the scores for each category are introduced. Between 4 and 20, the higher the score, the better the quality of life.

    Time frame: T4- 6 month later

  26. Mini-Mental State Examination

    Cognitive function will be assessed pre-enrollment using the MMSE, with validated age- and education-adjusted thresholds. The MMSE has demonstrated good reliability and validity and is a strong predictor of disability levels in patients with traumatic brain injury. Participants with an MMSE score below 24 will be excluded from the study to ensure appropriate cognitive capacity for participation. The score range is 0-30 points, with the international standard cut-off value of 24 points, 18-24 points as mild dementia, 16-17 points as moderate dementia, and ≦15 points as severe dementia.

    Time frame: T0- baseline

  27. Mini-Mental State Examination

    Cognitive function will be assessed pre-enrollment using the MMSE, with validated age- and education-adjusted thresholds \[75\]. The MMSE has demonstrated good reliability and validity and is a strong predictor of disability levels in patients with traumatic brain injury \[76\]. Participants with an MMSE score below 24 will be excluded from the study to ensure appropriate cognitive capacity for participation. The score range is 0-30 points, with the international standard cut-off value of 24 points, 18-24 points as mild dementia, 16-17 points as moderate dementia, and ≦15 points as severe dementia.

    Time frame: T1-1 month later

  28. Mini-Mental State Examination

    Cognitive function will be assessed pre-enrollment using the MMSE, with validated age- and education-adjusted thresholds \[75\]. The MMSE has demonstrated good reliability and validity and is a strong predictor of disability levels in patients with traumatic brain injury \[76\]. Participants with an MMSE score below 24 will be excluded from the study to ensure appropriate cognitive capacity for participation. The score range is 0-30 points, with the international standard cut-off value of 24 points, 18-24 points as mild dementia, 16-17 points as moderate dementia, and ≦15 points as severe dementia.

    Time frame: T2-2 month later

  29. Mini-Mental State Examination

    Cognitive function will be assessed pre-enrollment using the MMSE, with validated age- and education-adjusted thresholds. The MMSE has demonstrated good reliability and validity and is a strong predictor of disability levels in patients with traumatic brain injury. Participants with an MMSE score below 24 will be excluded from the study to ensure appropriate cognitive capacity for participation. The score range is 0-30 points, with the international standard cut-off value of 24 points, 18-24 points as mild dementia, 16-17 points as moderate dementia, and ≦15 points as severe dementia.

    Time frame: T3-3 month later

  30. Mini-Mental State Examination

    Cognitive function will be assessed pre-enrollment using the MMSE, with validated age- and education-adjusted thresholds. The MMSE has demonstrated good reliability and validity and is a strong predictor of disability levels in patients with traumatic brain injury. Participants with an MMSE score below 24 will be excluded from the study to ensure appropriate cognitive capacity for participation. The score range is 0-30 points, with the international standard cut-off value of 24 points, 18-24 points as mild dementia, 16-17 points as moderate dementia, and ≦15 points as severe dementia.

    Time frame: T4- 6 month later

  31. Montreal Cognitive Assessment

    The Montreal Cognitive Assessment (MoCA) is a sensitive tool for the early screening of mild cognitive impairment, particularly useful for detecting deficits in executive function, attention, short-term memory, language fluency, abstract thinking, and visuospatial abilities. The total score of the scale is 30 points, with a score of less than 26 considered indicative of possible mild cognitive impairment. The score can be adjusted (+1 point) based on educational level. The Chinese version of MoCA has been proven to have good reliability and validity (Cronbach's α = 0.83) and is particularly suitable for research populations in Asian regions.

    Time frame: T0-baseline

  32. Montreal Cognitive Assessment

    The Montreal Cognitive Assessment (MoCA) is a sensitive tool for the early screening of mild cognitive impairment, particularly useful for detecting deficits in executive function, attention, short-term memory, language fluency, abstract thinking, and visuospatial abilities. The total score of the scale is 30 points, with a score of less than 26 considered indicative of possible mild cognitive impairment. The score can be adjusted (+1 point) based on educational level. The Chinese version of MoCA has been proven to have good reliability and validity (Cronbach's α = 0.83) and is particularly suitable for research populations in Asian regions.

    Time frame: T1-1 month later

  33. Montreal Cognitive Assessment

    The Montreal Cognitive Assessment (MoCA) is a sensitive tool for the early screening of mild cognitive impairment, particularly useful for detecting deficits in executive function, attention, short-term memory, language fluency, abstract thinking, and visuospatial abilities. The total score of the scale is 30 points, with a score of less than 26 considered indicative of possible mild cognitive impairment. The score can be adjusted (+1 point) based on educational level. The Chinese version of MoCA has been proven to have good reliability and validity (Cronbach's α = 0.83) and is particularly suitable for research populations in Asian regions.

    Time frame: T2-2 month later

  34. Montreal Cognitive Assessment

    The Montreal Cognitive Assessment (MoCA) is a sensitive tool for the early screening of mild cognitive impairment, particularly useful for detecting deficits in executive function, attention, short-term memory, language fluency, abstract thinking, and visuospatial abilities. The total score of the scale is 30 points, with a score of less than 26 considered indicative of possible mild cognitive impairment. The score can be adjusted (+1 point) based on educational level. The Chinese version of MoCA has been proven to have good reliability and validity (Cronbach's α = 0.83) and is particularly suitable for research populations in Asian regions.

    Time frame: T3-3 month later

  35. Montreal Cognitive Assessment

    The Montreal Cognitive Assessment (MoCA) is a sensitive tool for the early screening of mild cognitive impairment, particularly useful for detecting deficits in executive function, attention, short-term memory, language fluency, abstract thinking, and visuospatial abilities. The total score of the scale is 30 points, with a score of less than 26 considered indicative of possible mild cognitive impairment. The score can be adjusted (+1 point) based on educational level. The Chinese version of MoCA has been proven to have good reliability and validity (Cronbach's α = 0.83) and is particularly suitable for research populations in Asian regions.

    Time frame: T4-6 month later

  36. Near-Infrared Brain Blood Flow Imaging

    In this study, the Biolight MediTECH® near-infrared brain blood flow imaging sensor (hemoencephalography; HEG) was used to measure blood flow in the prefrontal cortex. The Biolight near-infrared spectroscopy device is an HEG sensor designed by MediTECH®, based on NIR technology to observe the optical properties of cells and tissues at the reflection level. This enables monitoring of changes in oxyhemoglobin and deoxyhemoglobin concentrations. By measuring light absorption at different wavelengths, the system can continuously track changes during tissue oxidation processes, thereby measuring cerebral blood flow conditions. The percentage of the NIR brain blood flow ranged 0- 100%, the higher percentage means the higher prefrontal brain blood flow.

    Time frame: T0 - baseline

  37. Near-Infrared Brain Blood Flow Imaging

    In this study, the Biolight MediTECH® near-infrared brain blood flow imaging sensor (hemoencephalography; HEG) was used to measure blood flow in the prefrontal cortex. The Biolight near-infrared spectroscopy device is an HEG sensor designed by MediTECH®, based on NIR technology to observe the optical properties of cells and tissues at the reflection level. This enables monitoring of changes in oxyhemoglobin and deoxyhemoglobin concentrations. By measuring light absorption at different wavelengths, the system can continuously track changes during tissue oxidation processes, thereby measuring cerebral blood flow conditions. The percentage of the NIR brain blood flow ranged 0- 100%, the higher percentage means the higher prefrontal brain blood flow.

    Time frame: T1- 1 month later

  38. Near-Infrared Brain Blood Flow Imaging

    In this study, the Biolight MediTECH® near-infrared brain blood flow imaging sensor (hemoencephalography; HEG) was used to measure blood flow in the prefrontal cortex. The Biolight near-infrared spectroscopy device is an HEG sensor designed by MediTECH®, based on NIR technology to observe the optical properties of cells and tissues at the reflection level. This enables monitoring of changes in oxyhemoglobin and deoxyhemoglobin concentrations. By measuring light absorption at different wavelengths, the system can continuously track changes during tissue oxidation processes, thereby measuring cerebral blood flow conditions. The percentage of the NIR brain blood flow ranged 0- 100%, the higher percentage means the higher prefrontal brain blood flow.

    Time frame: T2-2 month later

  39. Near-Infrared Brain Blood Flow Imaging

    In this study, the Biolight MediTECH® near-infrared brain blood flow imaging sensor (hemoencephalography; HEG) was used to measure blood flow in the prefrontal cortex. The Biolight near-infrared spectroscopy device is an HEG sensor designed by MediTECH®, based on NIR technology to observe the optical properties of cells and tissues at the reflection level. This enables monitoring of changes in oxyhemoglobin and deoxyhemoglobin concentrations. By measuring light absorption at different wavelengths, the system can continuously track changes during tissue oxidation processes, thereby measuring cerebral blood flow conditions. The percentage of the NIR brain blood flow ranged 0- 100%, the higher percentage means the higher prefrontal brain blood flow.

    Time frame: T3- 3 month later

  40. Near-Infrared Brain Blood Flow Imaging

    In this study, the Biolight MediTECH® near-infrared brain blood flow imaging sensor (hemoencephalography; HEG) was used to measure blood flow in the prefrontal cortex. The Biolight near-infrared spectroscopy device is an HEG sensor designed by MediTECH®, based on NIR technology to observe the optical properties of cells and tissues at the reflection level. This enables monitoring of changes in oxyhemoglobin and deoxyhemoglobin concentrations. By measuring light absorption at different wavelengths, the system can continuously track changes during tissue oxidation processes, thereby measuring cerebral blood flow conditions. The percentage of the NIR brain blood flow ranged 0- 100%, the higher percentage means the higher prefrontal brain blood flow.

    Time frame: T4- 6 month later

  41. cardiac metabolic performance benchmark

    Preliminary findings from this study applied the cardiac metabolic performance benchmark (CMPB3) to compare the effectiveness of increasing cerebral blood circulation at different intensities (CMPB3 ≤ 35, 40, 45, 50). Results indicated that CMPB3 levels above 40 effectively increased cerebral blood circulation, with improvements observed not only during exercise but also during the post-exercise rest period, where cerebral blood flow remained higher than the baseline level. The lower intensity means the lower exercise intensity and the higher ability to perform aerobic walking exercise. The benchmark will be calculated by the Heart rate measured by Garmin fitness bracelet.

    Time frame: T0- baseline

  42. cardiac metabolic performance benchmark

    Preliminary findings from this study applied the cardiac metabolic performance benchmark (CMPB3) to compare the effectiveness of increasing cerebral blood circulation at different intensities (CMPB3 ≤ 35, 40, 45, 50). Results indicated that CMPB3 levels above 40 effectively increased cerebral blood circulation, with improvements observed not only during exercise but also during the post-exercise rest period, where cerebral blood flow remained higher than the baseline level. The lower intensity means the lower exercise intensity and the higher ability to perform aerobic walking exercise.

    Time frame: T1- 1 month later

  43. cardiac metabolic performance benchmark

    Preliminary findings from this study applied the cardiac metabolic performance benchmark (CMPB3) to compare the effectiveness of increasing cerebral blood circulation at different intensities (CMPB3 ≤ 35, 40, 45, 50). Results indicated that CMPB3 levels above 40 effectively increased cerebral blood circulation, with improvements observed not only during exercise but also during the post-exercise rest period, where cerebral blood flow remained higher than the baseline level. The lower intensity means the lower exercise intensity and the higher ability to perform aerobic walking exercise.

    Time frame: T2-2 month later

  44. cardiac metabolic performance benchmark

    Preliminary findings from this study applied the cardiac metabolic performance benchmark (CMPB3) to compare the effectiveness of increasing cerebral blood circulation at different intensities (CMPB3 ≤ 35, 40, 45, 50). Results indicated that CMPB3 levels above 40 effectively increased cerebral blood circulation, with improvements observed not only during exercise but also during the post-exercise rest period, where cerebral blood flow remained higher than the baseline level. The lower intensity means the lower exercise intensity and the higher ability to perform aerobic walking exercise.

    Time frame: T3- 3 month later

  45. cardiac metabolic performance benchmark

    Preliminary findings from this study applied the cardiac metabolic performance benchmark (CMPB3) to compare the effectiveness of increasing cerebral blood circulation at different intensities (CMPB3 ≤ 35, 40, 45, 50). Results indicated that CMPB3 levels above 40 effectively increased cerebral blood circulation, with improvements observed not only during exercise but also during the post-exercise rest period, where cerebral blood flow remained higher than the baseline level. The lower intensity means the lower exercise intensity and the higher ability to perform aerobic walking exercise.

    Time frame: T4- 6 month later

  46. Semi-Structured Interviews

    This study will adopt semi-structured interviews to gain an in-depth understanding of participants' experiences and perceptions of the digital exercise intervention, as well as to complement and interpret quantitative data. The interview content covers five major themes: 1. Overall experiences with wearable devices and LINE messages; 2. Exercise adherence and barriers; 3. Changes in exercise motivation; 4. Feedback and usability; 5. Suggestions for improvement. The data collected will be qualitative.

    Time frame: T1- 1 month later

  47. Semi-Structured Interviews

    This study will adopt semi-structured interviews to gain an in-depth understanding of participants' experiences and perceptions of the digital exercise intervention, as well as to complement and interpret quantitative data. The interview content covers five major themes: 1. Overall experiences with wearable devices and LINE messages; 2. Exercise adherence and barriers; 3. Changes in exercise motivation; 4. Feedback and usability; 5. Suggestions for improvement. The data collected will be qualitative.

    Time frame: T2- 2 month later

  48. Semi-Structured Interviews

    This study will adopt semi-structured interviews to gain an in-depth understanding of participants' experiences and perceptions of the digital exercise intervention, as well as to complement and interpret quantitative data. The interview content covers five major themes: 1. Overall experiences with wearable devices and LINE messages; 2. Exercise adherence and barriers; 3. Changes in exercise motivation; 4. Feedback and usability; 5. Suggestions for improvement. The data collected will be qualitative.

    Time frame: T3-3 month later

  49. Semi-Structured Interviews

    This study will adopt semi-structured interviews to gain an in-depth understanding of participants' experiences and perceptions of the digital exercise intervention, as well as to complement and interpret quantitative data. The interview content covers five major themes: 1. Overall experiences with wearable devices and LINE messages; 2. Exercise adherence and barriers; 3. Changes in exercise motivation; 4. Feedback and usability; 5. Suggestions for improvement. The data collected will be qualitative.

    Time frame: T4- 6 month later

  50. Physiological Monitoring Tools

    Garmin Vivosmart 5. This wearable device will track heart rate, exercise frequency, exercise duration, exercise intensity, step count, and sleep data. Data will be integrated with the Garmin Connect app for real-time monitoring and feedback. A preliminary study conducted by our research team in 2020 showed a high correlation (r = 0.91) between heart rate measurements obtained from the Garmin Vivosmart and the Zephyr BioHarness, supporting its use for home-based heart rate monitoring. Participants will wear the device at home to facilitate real-time tracking of exercise intensity and physiological responses during the intervention. Advanced sleep tracking in compatible Garmin devices incorporates multiple factors to provide information on sleep patterns. In addition to basic information, such as sleep onset and wake-up time, researchers will be able to obtain data on periods of wakefulness and time spent in key sleep stages, including light, deep, and rapid eye movement (REM) sleep.

    Time frame: T0- baseline

  51. Physiological Monitoring Tools

    Garmin Vivosmart 5. This wearable device will track heart rate, exercise frequency, exercise duration, exercise intensity, step count, and sleep data. Data will be integrated with the Garmin Connect app for real-time monitoring and feedback. A preliminary study conducted by our research team in 2020 showed a high correlation (r = 0.91) between heart rate measurements obtained from the Garmin Vivosmart and the Zephyr BioHarness, supporting its use for home-based heart rate monitoring. Participants will wear the device at home to facilitate real-time tracking of exercise intensity and physiological responses during the intervention. Advanced sleep tracking in compatible Garmin devices incorporates multiple factors to provide information on sleep patterns. In addition to basic information, such as sleep onset and wake-up time, researchers will be able to obtain data on periods of wakefulness and time spent in key sleep stages, including light, deep, and rapid eye movement (REM) sleep.

    Time frame: T1- 1 month later

  52. Physiological Monitoring Tools

    Garmin Vivosmart 5. This wearable device will track heart rate, exercise frequency, exercise duration, exercise intensity, step count, and sleep data. Data will be integrated with the Garmin Connect app for real-time monitoring and feedback. A preliminary study conducted by our research team in 2020 showed a high correlation (r = 0.91) between heart rate measurements obtained from the Garmin Vivosmart and the Zephyr BioHarness, supporting its use for home-based heart rate monitoring. Participants will wear the device at home to facilitate real-time tracking of exercise intensity and physiological responses during the intervention. Advanced sleep tracking in compatible Garmin devices incorporates multiple factors to provide information on sleep patterns. In addition to basic information, such as sleep onset and wake-up time, researchers will be able to obtain data on periods of wakefulness and time spent in key sleep stages, including light, deep, and rapid eye movement (REM) sleep.

    Time frame: T2-2 month later

  53. Physiological Monitoring Tools

    Garmin Vivosmart 5. This wearable device will track heart rate, exercise frequency, exercise duration, exercise intensity, step count, and sleep data. Data will be integrated with the Garmin Connect app for real-time monitoring and feedback. A preliminary study conducted by our research team in 2020 showed a high correlation (r = 0.91) between heart rate measurements obtained from the Garmin Vivosmart and the Zephyr BioHarness, supporting its use for home-based heart rate monitoring. Participants will wear the device at home to facilitate real-time tracking of exercise intensity and physiological responses during the intervention. Advanced sleep tracking in compatible Garmin devices incorporates multiple factors to provide information on sleep patterns. In addition to basic information, such as sleep onset and wake-up time, researchers will be able to obtain data on periods of wakefulness and time spent in key sleep stages, including light, deep, and rapid eye movement (REM) sleep.

    Time frame: T3-3 month later

  54. Physiological Monitoring Tools

    Garmin Vivosmart 5. This wearable device will track heart rate, exercise frequency, exercise duration, exercise intensity, step count, and sleep data. Data will be integrated with the Garmin Connect app for real-time monitoring and feedback. A preliminary study conducted by our research team in 2020 showed a high correlation (r = 0.91) between heart rate measurements obtained from the Garmin Vivosmart and the Zephyr BioHarness, supporting its use for home-based heart rate monitoring. Participants will wear the device at home to facilitate real-time tracking of exercise intensity and physiological responses during the intervention. Advanced sleep tracking in compatible Garmin devices incorporates multiple factors to provide information on sleep patterns. In addition to basic information, such as sleep onset and wake-up time, researchers will be able to obtain data on periods of wakefulness and time spent in key sleep stages, including light, deep, and rapid eye movement (REM) sleep.

    Time frame: T4- 6 month later

  55. The mHealth App usability questionnaire

    The Mobile App Usability Questionnaire (MAUQ) assesses usability across three dimensions: usability and satisfaction, system information arrangement, and system efficiency. A Chinese version of the questionnaire was developed in 2022, with an internal consistency reliability (Cronbach's α) of 0.988 and an internal consistency range of 0.845-0.931. The test-retest reliability ranges from 0.828 to 0.918. A total of 21 items, Likert scale scores ranged from 1 (strongly agree) to 7 (strongly disagree), indicating the lower scores the better usability.

    Time frame: T1- 1 month later

  56. The mHealth App usability questionnaire

    The Mobile App Usability Questionnaire (MAUQ) assesses usability across three dimensions: usability and satisfaction, system information arrangement, and system efficiency. A Chinese version of the questionnaire was developed in 2022, with an internal consistency reliability (Cronbach's α) of 0.988 and an internal consistency range of 0.845-0.931. The test-retest reliability ranges from 0.828 to 0.918. A total of 21 items, Likert scale scores ranged from 1 (strongly agree) to 7 (strongly disagree), indicating the lower scores the better usability.

    Time frame: T2- 2 month later

  57. The mHealth App usability questionnaire

    The Mobile App Usability Questionnaire (MAUQ) assesses usability across three dimensions: usability and satisfaction, system information arrangement, and system efficiency. A Chinese version of the questionnaire was developed in 2022, with an internal consistency reliability (Cronbach's α) of 0.988 and an internal consistency range of 0.845-0.931. The test-retest reliability ranges from 0.828 to 0.918. A total of 21 items, Likert scale scores ranged from 1 (strongly agree) to 7 (strongly disagree), indicating the lower scores the better usability.

    Time frame: T3- 3 month later

  58. The mHealth App usability questionnaire

    The Mobile App Usability Questionnaire (MAUQ) assesses usability across three dimensions: usability and satisfaction, system information arrangement, and system efficiency. A Chinese version of the questionnaire was developed in 2022, with an internal consistency reliability (Cronbach's α) of 0.988 and an internal consistency range of 0.845-0.931. The test-retest reliability ranges from 0.828 to 0.918. A total of 21 items, Likert scale scores ranged from 1 (strongly agree) to 7 (strongly disagree), indicating the lower scores the better usability.

    Time frame: T4- 6 month later

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2030, 52 months after the start.

Of 445 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 52 months is above that.

Counting every sponsor, half of 467 studies reached it within 41 months; a quarter within 22 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2025
First posted
Feb 10, 2025
StartActual
Aug 17, 2026
Primary completionEst.
Dec 31, 2030
CompletionEst.
Aug 31, 2031
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 13, 2026
Sites
1 site added — first site in Taiwan
Show site
  • Tri-Service General Hospital · Taipei, Taiwan
Nov 13, 2026
Eligibility
1 inclusion criterion edited, 2 added, 2 removed; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedEligible participants are patients aged over 1818 years or older with mild TBI (GCS 13-15) diagnosed within the previous 6 months.
  • Removedwho can walk independently,
  • Removedreside in the Greater Taipei area,
  • Addedwho can walk independently and have been cleared by the attending physician to participate in exercise.
  • Addedhave access to a smartphone and can use mobile messaging and wearable device applications.
Exclusion criteria
  • EditedPatients regularly engaging in moderate-to-high-intensity aerobic exercise orconcurrently participating in other studiesclinical trials or structured exercise programs will also be excluded to avoid bias.
Nov 13, 2026
Primary outcomes
14 time frame changed, 6 removed, 4 description edited
What changed in the outcomes
  • RemovedAdherenceTime frame: T5- 6 month later
  • RemovedThe mHealth App usability questionnaireTime frame: T1- baseline
  • RemovedThe mHealth App usability questionnaireTime frame: T2- 1 month later
  • RemovedThe mHealth App usability questionnaireTime frame: T3- 2 month later
  • RemovedThe mHealth App usability questionnaireTime frame: T4- 3 month later
  • RemovedThe mHealth App usability questionnaireTime frame: T5- 6 month later
  • Time frameAdherenceT1-baseline → T1- 1 month later
  • Time frameAdherence#2T2- 1 month later → T2- 2 month later
  • Time frameAdherence#3T3- 2 month later → T3- 3 month later
  • Time frameAdherence#4T4- 3 month later → T4- 6 month later
  • Time frameThe Chinese Version of the Sport Motivation Scale-IIT1- baseline → T0- baseline
  • Time frameThe Chinese Version of the Sport Motivation Scale-II#2T2- 1 month later → T1- 1 month later
  • Time frameThe Chinese Version of the Sport Motivation Scale-II#3T3- 2 month later → T2- 2 month later
  • Time frameThe Chinese Version of the Sport Motivation Scale-II#4T4- 3 month later → T3- 3 month later
  • Time frameThe Chinese Version of the Sport Motivation Scale-II#5T5- 6 month later → T4- 6 month later
  • Time frame6-Minute Walk TestT1- baseline → T0- baseline
  • Time frame6-Minute Walk Test#2T2- 1 month later → T1- 1 month later
  • Time frame6-Minute Walk Test#3T3- 2 month later → T2- 2 month later
  • Time frame6-Minute Walk Test#4T4- 3 month later → T3- 3 month later
  • Time frame6-Minute Walk Test#5T5- 6 month later → T4- 6 month later
  • DescriptionAdherence: how it is measured was reworded
  • DescriptionAdherence#2: how it is measured was reworded
  • DescriptionAdherence#3: how it is measured was reworded
  • DescriptionAdherence#4: how it is measured was reworded
Nov 13, 2026
Secondary outcomes
25 time frame changed, 4 added, 1 removed, 33 more
What changed in the outcomes
  • AddedThe mHealth App usability questionnaireTime frame: T1- 1 month later
  • AddedThe mHealth App usability questionnaireTime frame: T2- 2 month later
  • AddedThe mHealth App usability questionnaireTime frame: T3- 3 month later
  • AddedThe mHealth App usability questionnaireTime frame: T4- 6 month later
  • RemovedSemi-Structured InterviewsTime frame: T5- 6 month later
  • Time frameThe Rivermead Post-Concussion Symptoms QuestionnaireT1- baseline → T0- baseline
  • Time frameThe Rivermead Post-Concussion Symptoms Questionnaire#2T2- 1 month later → T1- 1 month later
  • Time frameThe Rivermead Post-Concussion Symptoms Questionnaire#3T3- 2 month later → T2- 2 month later
  • Time frameThe Rivermead Post-Concussion Symptoms Questionnaire#4T4- 3 month later → T3- 3 month later
  • Time frameThe Rivermead Post-Concussion Symptoms Questionnaire#5T5- 6 month → T4- 6 month
  • Time frameThe Beck Depression Inventory-IIT1- baseline → T0- baseline
  • Time frameThe Beck Depression Inventory-II#2T2-1 month later → T1-1 month later
  • Time frameThe Beck Depression Inventory-II#3T3- 2 month later → T2- 2 month later
  • Time frameThe Beck Depression Inventory-II#4T4-3 month later → T3-3 month later
  • Time frameThe Beck Depression Inventory-II#5T5- 6 month later → T4- 6 month later
  • Time frameThe Pittsburgh Sleep Quality IndexT1-baseline → T0-baseline
  • Time frameThe Pittsburgh Sleep Quality Index#2T2- 1 month later → T1- 1 month later
  • Time frameThe Pittsburgh Sleep Quality Index#3T3-2 month later → T2-2 month later
  • Time frameThe Pittsburgh Sleep Quality Index#4T4-3 month later → T3-3 month later
  • Time frameThe Pittsburgh Sleep Quality Index#5T5-6 month later → T4-6 month later
  • Time frameThe Godin-Shephard Leisure Time Physical Activity QuestionnaireT1 -baseline → T0 -baseline
  • Time frameThe Godin-Shephard Leisure Time Physical Activity Questionnaire#2T2 -1 month later → T1 -1 month later
  • Time frameThe Godin-Shephard Leisure Time Physical Activity Questionnaire#3T3 -2 month later → T2 -2 month later
  • Time frameThe Godin-Shephard Leisure Time Physical Activity Questionnaire#4T4-3 month later → T3-3 month later
  • Time frameThe Godin-Shephard Leisure Time Physical Activity Questionnaire#5T5-6 month later → T4-6 month later
  • Time frameThe World Health Organization Quality of Life Scale-briefT1 - baseline → T0 - baseline
  • Time frameThe World Health Organization Quality of Life Scale-brief#2T2 - 1 month later → T1 - 1 month later
  • Time frameThe World Health Organization Quality of Life Scale-brief#3T3 - 2 month later → T2 - 2 month later
  • Time frameThe World Health Organization Quality of Life Scale-brief#4T4 - 3 month later → T3- 3 month later
  • Time frameThe World Health Organization Quality of Life Scale-brief#5T5- 6 month later → T4- 6 month later
  • …and 33 more, on the record history on ClinicalTrials.gov ↗
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Taiwan
    Show site
    • Tri-Service General Hospital · Taipei, Taiwan
    Eligibility 1 inclusion criterion edited, 2 added, 2 removed; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedEligible participants are patients aged over 1818 years or older with mild TBI (GCS 13-15) diagnosed within the previous 6 months.
    • Removedwho can walk independently,
    • Removedreside in the Greater Taipei area,
    • Addedwho can walk independently and have been cleared by the attending physician to participate in exercise.
    • Addedhave access to a smartphone and can use mobile messaging and wearable device applications.
    Exclusion criteria
    • EditedPatients regularly engaging in moderate-to-high-intensity aerobic exercise orconcurrently participating in other studiesclinical trials or structured exercise programs will also be excluded to avoid bias.
    Primary outcomes 14 time frame changed, 6 removed, 4 description edited
    What changed in the outcomes
    • RemovedAdherenceTime frame: T5- 6 month later
    • RemovedThe mHealth App usability questionnaireTime frame: T1- baseline
    • RemovedThe mHealth App usability questionnaireTime frame: T2- 1 month later
    • RemovedThe mHealth App usability questionnaireTime frame: T3- 2 month later
    • RemovedThe mHealth App usability questionnaireTime frame: T4- 3 month later
    • RemovedThe mHealth App usability questionnaireTime frame: T5- 6 month later
    • Time frameAdherenceT1-baseline → T1- 1 month later
    • Time frameAdherence#2T2- 1 month later → T2- 2 month later
    • Time frameAdherence#3T3- 2 month later → T3- 3 month later
    • Time frameAdherence#4T4- 3 month later → T4- 6 month later
    • Time frameThe Chinese Version of the Sport Motivation Scale-IIT1- baseline → T0- baseline
    • Time frameThe Chinese Version of the Sport Motivation Scale-II#2T2- 1 month later → T1- 1 month later
    • Time frameThe Chinese Version of the Sport Motivation Scale-II#3T3- 2 month later → T2- 2 month later
    • Time frameThe Chinese Version of the Sport Motivation Scale-II#4T4- 3 month later → T3- 3 month later
    • Time frameThe Chinese Version of the Sport Motivation Scale-II#5T5- 6 month later → T4- 6 month later
    • Time frame6-Minute Walk TestT1- baseline → T0- baseline
    • Time frame6-Minute Walk Test#2T2- 1 month later → T1- 1 month later
    • Time frame6-Minute Walk Test#3T3- 2 month later → T2- 2 month later
    • Time frame6-Minute Walk Test#4T4- 3 month later → T3- 3 month later
    • Time frame6-Minute Walk Test#5T5- 6 month later → T4- 6 month later
    • DescriptionAdherence: how it is measured was reworded
    • DescriptionAdherence#2: how it is measured was reworded
    • DescriptionAdherence#3: how it is measured was reworded
    • DescriptionAdherence#4: how it is measured was reworded
    Secondary outcomes 25 time frame changed, 4 added, 1 removed, 33 more
    What changed in the outcomes
    • AddedThe mHealth App usability questionnaireTime frame: T1- 1 month later
    • AddedThe mHealth App usability questionnaireTime frame: T2- 2 month later
    • AddedThe mHealth App usability questionnaireTime frame: T3- 3 month later
    • AddedThe mHealth App usability questionnaireTime frame: T4- 6 month later
    • RemovedSemi-Structured InterviewsTime frame: T5- 6 month later
    • Time frameThe Rivermead Post-Concussion Symptoms QuestionnaireT1- baseline → T0- baseline
    • Time frameThe Rivermead Post-Concussion Symptoms Questionnaire#2T2- 1 month later → T1- 1 month later
    • Time frameThe Rivermead Post-Concussion Symptoms Questionnaire#3T3- 2 month later → T2- 2 month later
    • Time frameThe Rivermead Post-Concussion Symptoms Questionnaire#4T4- 3 month later → T3- 3 month later
    • Time frameThe Rivermead Post-Concussion Symptoms Questionnaire#5T5- 6 month → T4- 6 month
    • Time frameThe Beck Depression Inventory-IIT1- baseline → T0- baseline
    • Time frameThe Beck Depression Inventory-II#2T2-1 month later → T1-1 month later
    • Time frameThe Beck Depression Inventory-II#3T3- 2 month later → T2- 2 month later
    • Time frameThe Beck Depression Inventory-II#4T4-3 month later → T3-3 month later
    • Time frameThe Beck Depression Inventory-II#5T5- 6 month later → T4- 6 month later
    • Time frameThe Pittsburgh Sleep Quality IndexT1-baseline → T0-baseline
    • Time frameThe Pittsburgh Sleep Quality Index#2T2- 1 month later → T1- 1 month later
    • Time frameThe Pittsburgh Sleep Quality Index#3T3-2 month later → T2-2 month later
    • Time frameThe Pittsburgh Sleep Quality Index#4T4-3 month later → T3-3 month later
    • Time frameThe Pittsburgh Sleep Quality Index#5T5-6 month later → T4-6 month later
    • Time frameThe Godin-Shephard Leisure Time Physical Activity QuestionnaireT1 -baseline → T0 -baseline
    • Time frameThe Godin-Shephard Leisure Time Physical Activity Questionnaire#2T2 -1 month later → T1 -1 month later
    • Time frameThe Godin-Shephard Leisure Time Physical Activity Questionnaire#3T3 -2 month later → T2 -2 month later
    • Time frameThe Godin-Shephard Leisure Time Physical Activity Questionnaire#4T4-3 month later → T3-3 month later
    • Time frameThe Godin-Shephard Leisure Time Physical Activity Questionnaire#5T5-6 month later → T4-6 month later
    • Time frameThe World Health Organization Quality of Life Scale-briefT1 - baseline → T0 - baseline
    • Time frameThe World Health Organization Quality of Life Scale-brief#2T2 - 1 month later → T1 - 1 month later
    • Time frameThe World Health Organization Quality of Life Scale-brief#3T3 - 2 month later → T2 - 2 month later
    • Time frameThe World Health Organization Quality of Life Scale-brief#4T4 - 3 month later → T3- 3 month later
    • Time frameThe World Health Organization Quality of Life Scale-brief#5T5- 6 month later → T4- 6 month later
    • …and 33 more, on the record history on ClinicalTrials.gov ↗
    + 5 other changes: verification date, date precision, description, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06817564
Lead sponsor
National Defense Medical Center, Taiwan
Responsible party
Hui-Hsun Chiang (Professor, National Defense Medical Center, Taiwan) — Principal investigator
First posted
Feb 10, 2025
Start date
Aug 17, 2026
Primary completion
Dec 31, 2030 (estimated)
Completion
Aug 31, 2031 (estimated)
Last update
Nov 13, 2026

Study contacts

Hui-Hsun Chiang, Professor
Contact
sheisvivian@gmail.com
886-2-87923100 ext. 18761
Hui-Hsun Chiang, Professor
Contact
huihsunchiang@mail.ndmctsgh.edu.tw
886-921060383

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion